David Ricks

Eli Lilly Soars Past Q2 Estimates Driven by Blockbuster Weight-Loss and Diabetes Drugs; Raises Full-Year Outlook

Eli Lilly reported an impressive second quarter, surpassing earnings and revenue estimates, largely driven…